Cooper Pharma Launches First National Debate on Treatment Adherence, Prioritizing Hypertension in Health Concerns
Cooper Pharma organized today in Casablanca the inaugural edition of the National Debate on Treatment Adherence, aiming to highlight a silent yet critical health challenge: ensuring patients follow their treatment for hypertension and maintain ongoing monitoring.
Data reveals that approximately 29.3% of adults in Morocco suffer from high blood pressure, while adherence rates to treatment range from only 53.3% to 58.3%. This significantly undermines the effectiveness of medical care and increases the likelihood of serious cardiovascular complications. Studies indicate that non-adherence to treatment boosts the risk of cardiovascular events by about 60%, with direct repercussions on patient health and mortality rates, along with an economic burden estimated at around 40,000 dirhams annually per patient.
The debate brings together experts and professionals from various sectors of the health system, alongside national and international organizations and industry stakeholders, aiming to exchange experiences and initiate practical, sustainable solutions to enhance treatment adherence among patients. More than a hundred specialists participated in the event, and five prominent speakers presented their insights on best practices and treatment monitoring methods.
In a statement on the occasion, Moulay Saqli, executive director at Cooper Pharma, stated, “Treatment adherence has become a real challenge today, especially with chronic and silent diseases like hypertension. Our goal with this debate is to unify the efforts of various stakeholders to find practical solutions that enhance patients’ quality of life and improve healthcare effectiveness.”
Founded in 1933, Cooper Pharma is one of the leading pharmaceutical companies in Morocco, employing over 1,500 staff with an annual production capacity exceeding 42 million units. Through this initiative, the company reaffirms its commitment to enhancing public health and contributing to the development of the national health system, going beyond its traditional industrial role.
